Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

24-week Open-label Extension Study Evaluating the Effect of PXT00864 in Mild Alzheimer's Disease Patients Further to PLEODIAL-I Completion

NCT02361242 is registered in ClinicalTrials.gov with Pharnext S.C.A. as lead sponsor.

NCT NCT02361242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02361242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
24-week Open-label Extension Study Evaluating the Effect of PXT00864 in Mild Alzheimer's Disease Patients Further to PLEODIAL-I Completion
Lead sponsor
Pharnext S.C.A.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2013
Completion date
December 31, 2015
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease